InsidersTradesSigma
Total declarations
Companies
▲ Purchases (3 ops.)
▼ Sales (4 ops.)
Browse the complete record of transactions filed by JEFFS ROGER, Chief Executive Officer. Director active across 2 companies, notably Liquidia Corp. Aggregated, 12 filings have been published. Total volume traded: €4.5m. The latest transaction was filed on 13 May 2026 — Cession. Regulator: SEC (Form 4). The full history is accessible without signup.
Declarations12 total
€1m25,000 shares@ €48.0410.024% mcap58.4% of flow
Common Stock
SEC:0001104659-26-062852·
€1m25,000 shares@ €48.0410.024% mcap28.6% of flow
Common Stock
SEC:0001104659-26-062852:0·
US$855,76325,000 shares@ US$34.23050.017% mcap41.6% of flow
Common Stock
SEC:0001104659-26-057339·
€855,76325,000 shares@ €34.23050.017% mcap20.3% of flow
Common Stock
SEC:0001104659-26-057339:0·
13,834 shares
Common Stock
SEC:0001104659-26-043262·
13,834 shares
Common Stock
SEC:0001104659-26-043262:0·
13,834 shares
Common Stock
SEC:0001104659-25-099747·
13,834 shares
Common Stock
SEC:0001104659-25-099747:0·
€92,03428,000 shares@ €3.28690.0018% mcap2.2% of flow
Common Stock
SEC:0001104659-22-064800:0·
Ideal exit: 18 Feb 2023 (T+270)
0154,167 shares0
Common Stock
SEC:0001104659-22-047869:0·
€129,6133,950 shares@ €32.8135100.0% of flow
Common Stock
SEC:0001209191-21-066287·
Ideal exit: 16 Aug 2022 (T+270)
€129,6133,950 shares@ €32.81350.0014% mcap50.0% of flow
Common Stock
SEC:0001209191-21-066287:0·
Ideal exit: 16 Aug 2022 (T+270)
12 of 12 declarations
About JEFFS ROGER
Roger Jeffs is the Chief Executive Officer of Liquidia Corp and Axsome Therapeutics, Inc. With significant experience in the biopharmaceutical sector, he leads strategic initiatives to promote innovation and growth within these companies. His vision and leadership are essential for navigating a complex and ever-evolving environment.
